Clinical trial
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney…
NCT00003714 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00003714 |
|---|---|
| Title | Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer |
| Official title | Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | Pyrazoloacridine |
| Enrollment | 0 |
| First posted | Sep 14, 2004 |
| Last update posted | Feb 22, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: